Sipra

What Sipra does

Sipra Labs Limited is a privately held, Hyderabad-based Contract Research Organization (CRO) founded in 1994 that provides regulatory-compliant research and testing services to pharmaceutical, biotechnology, and medical device companies. The company organizes its offering into seven service lines: Analytical Services (cGMP-compliant impurity profiling, method development and validation, stability and microbiological studies), Medical Device Services (ISO 10993 biocompatibility, ISO 11607 packaging, ASTM mechanical testing), Bio Pharma Services (RT-PCR gene analysis, SDS-PAGE, Western Blot, peptide mapping, biosimilar characterization), Formulation Research Services (pre-formulation through CTD dossier preparation for tablets, capsules, suspensions, syrups, and injectables), BA/BE Services (DCGI-approved bioavailability and bioequivalence studies), Clinical Services (Phase II–IV trials, clinical pharmacology, biostatistics with SAS 9.4), and Pre-Clinical Toxicity Services (OECD GLP-compliant toxicology across multiple species). Operations target both global and indigenous pharma sponsors pursuing dossier submissions to USFDA, EMA, and PMDA markets, with named international recognitions from TGA Australia and Health Canada.

The technology platform centers on a 95,000 sft main facility in Sanathnagar, Hyderabad and a 20,500 sft GLP-compliant preclinical toxicology facility in Balanagar, Hyderabad, equipped with five LC-MS/MS units and supporting instrumentation including GC-MS/MS, ICP-MS, NMR, FT-IR, AAS, XRD, dissolution apparatus, and stability chambers. Clinical operations run across two clinics with 80 beds (including a 12-bed ICU with central online monitoring), supported by a 20,000+ healthy volunteer database and 150+ validated bioanalytical methods, with cumulative experience of 1,600+ BA/BE studies. The company carries an unusually dense accreditation stack — USFDA registration, DCGI BA/BE approval, NABL ISO/IEC 17025, OECD GLP, ISO 9001, ISO 27001 ISMS, ISO 14155, TGA Australia, Health Canada, CPCSEA, BIS, DCA, DBT-IBSC, and WHO — which functions as both a regulatory moat and a sales credential with global sponsors.

The business model is B2B project-based professional services sold via direct sales through business development managers, client relationship managers, and a web-enabled requisition portal, with quote-based pricing that is not publicly disclosed and standard turnaround of five working days for test reports. Revenue derives from seven complementary service lines across three primary segments (generic pharmaceutical companies, biotechnology companies, and medical device manufacturers) plus secondary segments in agrochemicals and food safety. Leadership is founder-controlled under Chairman & Managing Director Dr. V. Satyanarayana, Executive Director V. Shrihari, and Director Mrs V. Madhavi, with no external institutional investors, private equity backing, or public listing disclosed.

Name

Sipra

Legal name

Sipra Labs Limited

Website

https://sipralabs.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

51–100 employees

Short description

Sipra Labs Limited is a Hyderabad-based, USFDA-registered Contract Research Organization providing analytical, formulation, bioequivalence, clinical, preclinical, and medical device testing services to pharmaceutical, biotech, and medical device companies for global regulatory submissions.

Ownership category

akta.pro rank

Product category

Contract Research Organization Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Contract research services
• Analytical testing services
• Bioequivalence studies
• Preclinical toxicology
• Pharmaceutical testing

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services: Sipra generates revenue through providing comprehensive contract research and development services to pharmaceutical, biotech, and medical device industries. Services include analytical testing, preclinical studies, clinical trials, BA/BE studies, formulation development, and regulatory compliance testing. Revenue is project-based with clients engaging for specific testing or research needs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Sipra Labs Limited operates as a Contract Research Organization (CRO) offering end-to-end regulatory compliant research and developmental services to the pharmaceutical, biotech, and medical device industries. Services span analytical testing, formulation research, bioequivalence (BA/BE) studies, clinical trials, preclinical toxicology, and medical device testing, supporting dossier submissions to USFDA, Europe, and Japan markets.

Product overview

Sipra Labs Limited operates as a Contract Research Organization (CRO) offering an integrated, end-to-end portfolio of regulatory-compliant research and development services to the pharmaceutical, biotech, and medical device industries. The service offering is organized as seven distinct but complementary service lines: Analytical Services (GMP-compliant testing, impurity profiling, method development), Medical Device Services (biocompatibility, chemical, and packaging testing), Bio Pharma Services (biotech product analysis, biosimilar characterization), Formulation Research Services (drug development from pre-formulation to dossier preparation), BA/BE Services (bioavailability/bioequivalence clinical studies), Clinical Services (Phase II-IV clinical trials, biometrics), and Pre-Clinical Toxicity Services (GLP-compliant toxicology and efficacy studies). Together, these services cover the full drug and device development lifecycle from early-stage research through regulatory submission and post-marketing support.

Differentiator

Problem solved

Functional benefit

Products and services

• Analytical Services CGMP-compliant analytical testing facility offering comprehensive analytical testing services aligned with USFDA, TGA-Australia, and Health Canada regulatory requirements. Includes impurity profiling, analytical method development and validation, drug characterization, stability studies, microbiological studies, particle size characterization, and crystallographic studies for pharmaceutical manufacturers.
• Medical Device Services Single-stop solution for medical device testing from development through consumer delivery, compliant with global regulatory requirements. Includes OECD GLP-compliant biocompatibility testing (ISO 10993), chemical testing, NABL ISO 11607-compliant packaging material testing, and mechanical testing (ASTM).
• Bio Pharma Services Laboratory providing comprehensive quality product testing services for pharma and biotech companies. Capabilities include gene identification and quantification by RT-PCR, molecular size distribution, SDS PAGE, Western Blot, peptide mapping, protein impurity analysis, biosimilar analysis, and methods validation per ICH guidelines.
• Formulation Research Services Full-fledged formulation research and development activity encompassing pre-formulation studies, formulation development, analytical method development and validation, stability studies, and CTD-format dossier preparation. Develops various pharmaceutical dosage forms including tablets, capsules, suspensions, syrups, and injectables.
• BA/BE Services Bioavailability and bioequivalence centre approved by DCGI offering comprehensive clinical research services for generic, pharmaceutical, and biotech industries. Includes 2 clinics with 80 beds, ICU with 12 beds, GLP-compliant bioanalytical laboratory, and capabilities in PD/PK studies, BA/BE studies, and multi-dose studies.
• Clinical Services Global contract research services including clinical pharmacology (Phase II-IV studies), centralized investigation, clinical trial management, medical services, strategy development, and biostatistics with SAS (Version 9.4).
• Pre-Clinical Toxicity Services Preclinical toxicology (PCT) facility offering comprehensive preclinical services including toxicity studies, toxicokinetic studies, pharmacological studies, pharmacokinetic studies, drug metabolism studies, biocompatibility studies, genetic toxicology studies, and agrochemical testing. Facility spans 20,500 sft and is GLP-compliant per OECD, ICH, FDA, and ISO guidelines.

Quantifiable outcome

• 1600+ BA/BE studies conducted with 20,000+ volunteer database
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Veeda Clinical Research: Indian CRO specialising in BA/BE, bioanalytical, and clinical research for generics and biosimilars. Direct overlap with Sipra's BA/BE centre and bioanalytical lab; comparable regulatory positioning for ANDA-supporting work.
• Lotus Labs: India-based CRO offering analytical, formulation, and BA/BE services to generic pharma. Closely comparable mid-market Indian CRO peer with overlapping customer segments and service capabilities.
• Lambda Therapeutic Research: India-headquartered CRO providing clinical pharmacology, BA/BE, bioanalytical, and clinical trial services. Comparable service mix and target customer base of generic and innovative pharma sponsors filing into regulated markets.
• Syngene International: India-based integrated CRO/CDMO offering discovery, development, and analytical services to global pharma and biotech. Most direct Indian peer given comparable end-to-end offering, scale, and regulatory accreditations; Sipra is a smaller, more clinical/testing-focused analogue.

Regional players

• Sai Life Sciences: India-based CRO/CDMO offering drug discovery, development, and analytical services. Comparable India footprint and integrated CRO offering with comparable regulatory accreditations; more discovery-oriented than Sipra's clinical/analytical focus.

Broad incumbents

• Parexel International: Global CRO providing clinical, regulatory, and bioanalytical services to pharma/biotech. Competes with Sipra in bioequivalence, clinical, and regulatory submission services; substantially larger and globally diversified.
• Charles River Laboratories: Global CRO specialising in preclinical safety assessment, research models, and clinical/manufacturing services. Most direct overlap with Sipra's preclinical toxicology and BA/BE preclinical services, though at substantially larger scale.
• IQVIA: Global CRO and life sciences services giant offering clinical, real-world evidence, and technology-enabled solutions. Competes with Sipra for Phase II-IV clinical and bioanalytical work but at vastly larger scale and broader geographic reach.
• Labcorp Drug Development (formerly Covance): Global central lab and clinical CRO services provider offering bioanalytical, biomarker, and Phase I-IV services. Overlaps with Sipra's bioanalytical lab and clinical services at a global scale.
• ICON plc: Global clinical CRO with strong bioanalytical/laboratory services franchise (post-PRA Health combination). Competes with Sipra in Phase II-IV clinical and bioanalytical services and serves similar pharma/biotech sponsor base.

Market position

Strengths5 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/LabsSipra

Compliance18 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sipra